Management of chronic hepatitis B infection: an update.

dc.contributor.authorMazumdar, T Nen_US
dc.date.accessioned2001-06-27en_US
dc.date.accessioned2009-05-31T13:47:06Z
dc.date.available2001-06-27en_US
dc.date.available2009-05-31T13:47:06Z
dc.date.issued2001-06-27en_US
dc.description15 references.en_US
dc.description.abstractAlmost 43 million people in India are harbouring hepatitis B virus (HBV) in their blood. Chronic HBV infection may be with or without sign/symptom of liver disease. Children are more prone to suffer from chronic HBV infection compared to adults and adolescents. Treatment aims at prevention of its sequelae namely cirrhosis and subsequent hepatocellular carcinoma. At the moment two major groups of agents are available for treatment. These are (a) immunomodulators and (b) antivirals. Present research aims at identification of a suitable agent to act on HBV covalently closed circular DNA persisting in hepatic cells for complete eradication of HBV.en_US
dc.description.affiliationDepartment of Gastroenterology, VIMS, RKM Seva Pratisthan, Calcutta.en_US
dc.identifier.citationMazumdar TN. Management of chronic hepatitis B infection: an update. Journal of the Indian Medical Association. 2001 Jun; 99(6): 306-8, 310en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/102153
dc.language.isoengen_US
dc.source.urihttps://www.jimaonline.org.in/en_US
dc.subject.meshAntiviral Agents --therapeutic useen_US
dc.subject.meshHepatitis B, Chronic --drug therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshIndia --epidemiologyen_US
dc.subject.meshInterferon-alpha --therapeutic useen_US
dc.subject.meshLamivudine --therapeutic useen_US
dc.subject.meshPatient Selectionen_US
dc.subject.meshThymosin --therapeutic useen_US
dc.titleManagement of chronic hepatitis B infection: an update.en_US
dc.typeJournal Articleen_US
dc.typeReviewen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description: